Novel Biomarkers for Anticancer Therapy

140.2K

views

244

authors

33

articles

Editorial

06 January 2023

Editorial: Novel biomarkers for anticancer therapy

Ting Wang

,

Zhe-Sheng Chen

,

Chen Shi

,

Liang Ouyang

and

Hongtao Xiao

1,676 views

0 citations

Editors

5

University of Electronic Science and Technology of China

Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University

Sichuan University

Sichuan Cancer Hospital

Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Impact

Fetching...

About

Cancer is a life-threatening disease that imposes an economic burden on society. Diagnosing and treating carcinoma is a great challenge due to its complexity and therapeutic resistance. Despite recent advances in treatment strategies, such as immunotherapy and targeted therapy, the survival rate of cancer patients has reached plateau levels.

Tumor cells often exhibit primary or acquired resistance to therapy, consequently leading to treatment failure. Thus, besides the discovery of new anticancer targets, the identification of prognostic and predictive biomarkers becomes a crucial part of drug development nowadays, especially in the era of targeted therapy. Interestingly, the research about epigenetic alterations in cancer development and progression has recently led to new paradigms paving the way for innovative therapeutic strategies but also for new biomarkers.

This Research Topic aims to focus on novel biomarkers to be associated with anti-cancer drugs, including those related to the epigenetic regulation of cancer and drug response.

Cancer is a life-threatening disease that imposes an economic burden on society. Diagnosing and treating carcinoma is a great challenge due to its complexity and therapeutic resistance. Despite recent advances in treatment strategies, such as immunotherapy and targeted therapy, the survival rate of cancer patients has reached plateau levels.

Tumor cells often exhibit primary or acquired resistance to therapy, consequently leading to treatment failure. Thus, besides the discovery of new anticancer targets, the identification of prognostic and predictive biomarkers becomes a crucial part of drug development nowadays, especially in the era of targeted therapy. Interestingly, the research about epigenetic alterations in cancer development and progression has recently led to new paradigms paving the way for innovative therapeutic strategies but also for new biomarkers.

This Research Topic aims to focus on novel biomarkers to be associated with anti-cancer drugs, including those related to the epigenetic regulation of cancer and drug response.

Download ebook

Share

Editors

University of Electronic Science and Technology of China

Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University

Sichuan University

Sichuan Cancer Hospital

Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Impact

140,201 Total views

89,869 Article views

46,755 Article downloads

3,577 Topic views

Published In

Journal Thumbnail

Frontiers in Pharmacology

Pharmacology of Anti-Cancer Drugs

Journal Thumbnail

Frontiers in Oncology

Pharmacology of Anti-Cancer Drugs

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic